Nectar Lifesciences (NSE:NECLIFE) Cyclically Adjusted PB Ratio: (As of Sep. 01, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:NECLIFE Nectar Lifesciences Ltd NSE:NECLIFE
46 GF Score
Price ₹12.54
GF Value ₹6.86
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Nectar Lifesciences Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Nectar Lifesciences  (NSE:NECLIFE) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Nectar Lifesciences Cyclically Adjusted PB Ratio Related Terms


Nectar Lifesciences Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Nectar Lifesciences's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nectar Lifesciences Cyclically Adjusted PB Ratio Chart

Nectar Lifesciences Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.39 0.16

Nectar Lifesciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.24 0.00 0.16 0.00

NSE:NECLIFE vs ZTS: Cyclically Adjusted PB Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Nectar Lifesciences's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nectar Lifesciences Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Nectar Lifesciences's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Nectar Lifesciences's Cyclically Adjusted PB Ratio falls into.


NSE:NECLIFE
46GF Score
Nectar Lifesciences Ltd NSE:NECLIFE
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nectar Lifesciences Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Nectar Lifesciences's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Nectar Lifesciences's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0/167.3573*167.3573
=0.000

Current CPI (Jun. 2026) = 167.3573.

Nectar Lifesciences Quarterly Data

Book Value per Share CPI Adj_Book
201203 34.980 76.889 76.138
201303 38.687 85.687 75.560
201403 41.338 91.425 75.671
201503 40.222 97.163 69.280
201603 42.543 102.518 69.450
201703 44.889 105.196 71.414
201803 47.207 109.786 71.962
201806 0.000 111.317 0.000
201809 0.000 115.142 0.000
201812 0.000 115.142 0.000
201903 49.280 118.202 69.773
201906 0.000 120.880 0.000
201909 49.943 123.175 67.857
201912 0.000 126.235 0.000
202003 50.661 124.705 67.988
202006 0.000 127.000 0.000
202009 49.525 130.118 63.699
202012 0.000 130.889 0.000
202103 47.357 131.771 60.147
202106 0.000 134.084 0.000
202109 47.520 135.847 58.542
202112 0.000 138.161 0.000
202203 48.511 138.822 58.483
202206 0.000 142.347 0.000
202209 47.684 144.661 55.165
202212 0.000 145.763 0.000
202303 47.471 146.865 54.095
202306 0.000 150.280 0.000
202309 47.598 151.492 52.583
202312 0.000 152.924 0.000
202403 47.679 153.035 52.141
202406 0.000 155.789 0.000
202409 48.061 157.882 50.945
202412 0.000 158.323 0.000
202503 42.634 157.552 45.287
202506 0.000 159.755 0.000
202509 31.966 162.289 32.964
202512 0.000 163.281 0.000
202603 29.975 164.272 30.538
202606 0.000 167.357 0.000

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Nectar Lifesciences (NSE:NECLIFE) Overvalued in 2026?

Based on GuruFocus' analysis, Nectar Lifesciences stock appears to be overvalued. The current stock price of ₹12.54 is trading 82.8% above its estimated GF Value™ of ₹6.86. GuruFocus considers Nectar Lifesciences to be Significantly Overvalued.

Key valuation signals for NSE:NECLIFE:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: ₹6.86 vs. price of ₹12.54 (82.8% above fair value)
  • GF Score™: 46/100 with 3 warning signs

No single metric tells the full story. See the NSE:NECLIFE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Nectar Lifesciences Business Description

Other Exchanges 532649:India
Address S.C.O. 38-39, Sector 9-D, B-1011/1012, 10th Floor NAURANG HOUSE, Chandigarh, IND, 160009
Nectar Lifesciences Ltd is an India-based pharmaceutical company specializing in Cephalosporins. It is engaged in manufacturing specialized pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and finished dosage formulations. It operates in the business segment of Pharmaceuticals Products. The Company is also in the Menthol business and succeeded in both domestic and international markets. Its business areas are APIs, Formulations, and Empty Hard Gelatin Capsules. Geographically, it derives a majority of its revenue from India.
46GF Score

Get the complete analysis for NSE:NECLIFE

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹12.54
Price
₹6.86
GF Value